Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 217

The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.

Genomic profiling for clinical decision making in myeloid neoplasms and acute leukemia

Open access
Duncavage, Eric J., Bagg, Adam, Hasserjian, Robert P., DiNardo, Courtney D., Godley, Lucy A., Iacobucci, Ilaria, Jaiswal, Siddhartha, Malcovati, Luca, Vannucchi, Alessandro M., Patel, Keyur P., Arber, Daniel A., Arcila, Maria E., Bejar, Rafael, Berliner, Nancy, Borowitz, Michael J., Branford, Susan, Brown, Anna L., Cargo, Catherine A., Döhner, Hartmut, Falini, Brunangelo, Garcia-Manero, Guillermo, Haferlach, Torsten, Hellström-Lindberg, Eva, Kim, Annette S., Klco, Jeffery M., Komrokji, Rami, Lee-Cheun Loh, Mignon, Loghavi, Sanam, Mullighan, Charles G., Ogawa, Seishi, Orazi, Attilio, Papaemmanuil, Elli, Reiter, Andreas, Ross, David M., Savona, Michael, Shimamura, Akiko, Skoda, Radek C., Solé, Francesc, Stone, Richard M., Tefferi, Ayalew, Walter, Matthew J., Wu, David, Ebert, Benjamin L., Cazzola, Mario · 2022 · Blood

Abstract

Myeloid neoplasms and acute leukemias derive from the clonal expansion of hematopoietic cells driven by somatic gene mutations. Although assessment of morphology plays a crucial role in the diagnostic evaluation of patients with these malignancies, genomic characterization has become increasingly important for accurate diagnosis, risk assessment, and therapeutic decision making. Conventional cytogenetics, a comprehensive and unbiased method for assessing chromosomal abnormalities, has been the mainstay of genomic testing over the past several decades and remains relevant today. However, more recent advances in sequencing technology have increased our ability to detect somatic mutations through the use of targeted gene panels, whole-exome sequencing, whole-genome sequencing, and whole-transcriptome sequencing or RNA sequencing. In patients with myeloid neoplasms, whole-genome sequencing represents a potential replacement for both conventional cytogenetic and sequencing approaches, providing rapid and accurate comprehensive genomic profiling. DNA sequencing methods are used not only for detecting somatically acquired gene mutations but also for identifying germline gene mutations associated with inherited predisposition to hematologic neoplasms. The 2022 International Consensus Classification of myeloid neoplasms and acute leukemias makes extensive use of genomic data. The aim of this report is to help physicians and laboratorians implement genomic testing for diagnosis, risk stratification, and clinical decision making and illustrates the potential of genomic profiling for enabling personalized medicine in patients with hematologic neoplasms.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1182/blood.2022015853

Cites

30 of 30 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 217

Metadata

Authors
Duncavage, E. J., Bagg, A., Hasserjian, R. P., DiNardo, C. D., Godley, L. A., Iacobucci, I., Jaiswal, S., Malcovati, L., Vannucchi, A. M., Patel, K. P., Arber, D. A., Arcila, M. E., Bejar, R., Berliner, N., Borowitz, M. J., Branford, S., Brown, A. L., Cargo, C. A., Döhner, H., Falini, B., Garcia-Manero, G., Haferlach, T., Hellström-Lindberg, E., Kim, A. S., Klco, J. M., Komrokji, R., Lee-Cheun Loh, M., Loghavi, S., Mullighan, C. G., Ogawa, S., Orazi, A., Papaemmanuil, E., Reiter, A., Ross, D. M., Savona, M., Shimamura, A., Skoda, R. C., Solé, F., Stone, R. M., Tefferi, A., Walter, M. J., Wu, D., Ebert, B. L., & Cazzola, M.
Venue
Blood
Published
2022-11-24
Volume
140
Issue
21
Pages
2228-2247
ISSN
  • 0006-4971 (ISSN-L)
  • 1528-0020
OpenAlex
W4296710205
Cited by
217
References
30
FWCI
29.50
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.